TROG 99.02 - Anal Canal - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

Primary Sponsor

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof

13 November, 2024

Trek4TROG team rise to Blue Mountains challenge

November 2024: Congratulations to the Trek4TROG team for successfully

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Meet TROG President: A/Prof Puma Sandaresan

Trek4TROG team rise to Blue Mountains challenge

Register for the 2025 ASM

TROG 99.02 – Anal Canal

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Meet TROG President: A/Prof Puma Sandaresan

Trek4TROG team rise to Blue Mountains challenge

Register for the 2025 ASM